Patented platform technology capable of rapidly identifying vaccine components, producing new, effective vaccines and next-gen diagnostics.
AgilVax® Inc. is commercializing a virus-like particle (VLP) based vaccine platform technology under a worldwide, exclusive license. The platform, derived from RNA bacteriophages, is a cost-effective method for developing safe, efficacious vaccines for chronic and infectious diseases. It is the only VLP platform that facilitates both vaccine discovery and implementation. Moreover, it identifies components required to diagnose specific infections.